TELA Bio, Inc. is a commercial-stage medical technology company. Co. is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. Co.'s OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. The TELA average annual return since 2019 is shown above.
The Average Annual Return on the TELA average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TELA average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TELA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free TELA Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
